10x Genomics, Inc. TXG Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.
The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about 10x Genomics, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 10x Genomics, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
- 10x Genomics, Inc. (TXG) reported proceeds from maturities, prepayments and calls of debt securities, available-for-sale of $25M in Q1 2026.
- What is the long-term trend for 10x Genomics, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
- Over 2 years (2022 to 2025), 10x Genomics, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale has grown at a 159.9% compound annual growth rate (CAGR), from $18.53M to $125.2M.
- What does proceeds from maturities, prepayments and calls of debt securities, available-for-sale mean?
- This measures cash inflows resulting from the natural maturity or early redemption of debt securities held in the investment portfolio. It indicates the recurring cash generation from the company's fixed-income investment strategy.